AcuCort has received approval for the company’s first drug Zeqmelit® in Finland from the Finnish drug monitoring agency, Fimea. Thus, Zeqmelit® has been approved in all Nordic countries.
"An important milestone for the upcoming market launch of Zeqmelit® in the Nordics is achieved with this approval. We look with great confidence to the upcoming launch in the Nordics and continue the work to register Zeqmelit® in other prioritized markets", says Jonas Jönmark, CEO of AcuCort.
In the development of the drug Zeqmelit®, AcuCort has succeeded in combining the advantages of the well-proven substance dexamethasone and a patented user-friendly oral film for quick availability and relief in emergency situations such as severe and acute allergic reactions.
Zeqmelit® has previously been approved by pharmaceutical authorities in Sweden, Norway and Denmark. AcuCort's objective is to commercialize Zeqmelit® globally, i.e. in the EU, USA and in selected key markets.
This information is information that AcuCort AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 2023-01-24 08:30 CET.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark and Norway. All in all, it strengthens the company's assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.